COMP <GO>
HOWL vs IBIO // ALTMAN Z-SCORE & DEBT/EQUITY
Werewolf Therapeutics Inc. (NASDAQ) VS. iBio Inc. (NASDAQ) • 15-METRIC TALLY: HOWL 2
— IBIO 1
■ METRIC PARITY
LAST: $0.99 (-10.35%) • MKT CAP: $53.5M
balance-sheet
—
LAST: $0.77 (-5.52%) • MKT CAP: $52.3M
balance-sheet
0.20
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HOWL VS. IBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HOWL | IBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 77.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | IBIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 40.2 | +10.95 | HOWL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $53.5M | $52.3M | $1.1M | HOWL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HOWL REV | IBIO REV | HOWL GROSS % | IBIO GROSS % | HOWL FCF | IBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $400.0K | — | — | -$60.3M | -$15.3M |
| FY 2024 | $0 | $225.0K | — | — | -$56.4M | -$18.8M |
| FY 2023 | $0 | $0 | — | — | -$32.6M | -$30.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HOWL // BETA —
IBIO // BETA —